Cannabinoids and B cells: emerging targets for treating progressive multiple sclerosis

Hensiek AE Seaman SR Barcellos LF . Familial effects on the clinical course of multiple sclerosis. Neurology 2007; 68: 376–383.

DeLuca GC Ramagopalan SV Herrera BM . An extremes of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locus. Proc Natl Acad Sci U S A 2007; 104: 20896–20901.

Stankovich J Butzkueven H Marriott M . HLA-DRB1 associations with disease susceptibility and clinical course in Australians with multiple sclerosis. Tissue Antigens 2009; 74: 17–21.

Jensen CJ Stankovich J Van der Walt A . Multiple sclerosis susceptibility-associated SNPs do not influence disease severity measures in a cohort of Australian MS patients. PLoS ONE 2010; 5: e10003.

Rossi S Buttari F Studer V . The (AAT)n repeat of the cannabinoid CB1 receptor gene influences disease progression in relapsing multiple sclerosis. Mult Scler 2011.

Jackson SJ Diemel LT Pryce G Baker D . Cannabinoids and neuroprotection in CNS inflammatory disease. J Neurol Sci 2005; 233: 21–25.

Pryce G Ahmed Z Hankey DJ . Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 2003; 126: 2191–2202.

Peninsular Medical School. Cannabinoid Use in Progressive Inflammatory Brain Disease. . Plymouth: Peninsula Medical School, 2010.

Magliozzi R Howell O Vora A . Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007; 130: 1089–1104.

Prineas JW . Multiple sclerosis: presence of lymphatic capillaries and lymphoid tissue in the brain and spinal cord. Science 1979; 203: 1123–1125.

Wolinsky JS Narayana PA O'Connor P . Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 2007; 61: 14–24.

Joseph FG Hirst CL Pickersgill TP Ben-Shlomo Y Robertson NP Scolding NJ . CSF oligoclonal band status informs prognosis in multiple sclerosis: a case control study of 100 patients. J Neurol Neurosurg Psychiatry 2009; 80: 292–296.

Sola P Mandrioli J Simone AM . Primary progressive versus relapsing-onset multiple sclerosis: presence and prognostic value of cerebrospinal fluid oligoclonal IgM. Mult Scler 2011.

Stauch C Reiber H Rauchenzauner M . Intrathecal IgM synthesis in pediatric MS is not a negative prognostic marker of disease progression: Quantitative versus qualitative IgM analysis. Mult Scler 2011.

Krupp LB Banwell B Tenembaum S . Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology 2007; 68: S7–S12.

Zhao C Li WW Franklin RJ . Differences in the early inflammatory responses to toxin-induced demyelination are associated with the age-related decline in CNS remyelination. Neurobiol Aging 2006; 27: 1298–1307.

Khademi M Kockum I Andersson ML . Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. Mult Scler 2011.

Ruet A Deloire MS Ouallet JC Molinier S Brochet B . Predictive factors for multiple sclerosis in patients with clinically isolated spinal cord syndrome. Mult Scler 2011.

Hauser S Waubant E Arnold D . B-cell depletion with rituximab in relapsing–remitting multiple sclerosis. N Engl J Med 2008; 358: 676–688.

Kappos L O’Connor P Bar-Or A Li D Barkhof F Yin M . Efficacy and safety of ocrelizumab in patients with relapsing–remitting multiple sclerosis: results of a phase II randomised placebo-controlled multicentre trial. Multiple Sclerosis 2010; 16: S7–S39; abstract 114).

Soelberg Sorensen P Havrdova E Lisby S Graff O Shackelford S . Magnetic resonance imaging (MRI) efficacy of ofatumumab in relapsing–remitting multiple sclerosis (RRMS) – 24-week results of a phase II study. Multiple Sclerosis 2010; 16: S7–S39; abstract 136).

Hawker K O'Connor P Freedman MS . Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009; 66: 460–471.

clinicaltrials.gov. Double blind combination of rituximab by intravenous and intrathecal injection versus placebo in patients with low-inflammatory secondary progressive multiple sclerosis (RIVITaLISe). Bethesda, MD: NIH, 2010.